Literature DB >> 23860152

Morvan syndrome: after scrotal sac drainage and chemical instillation in hydrocele.

Sanjay Sharma1, Pranita Sharma.   

Abstract

We have described the occurrence of Morvan syndrome (MoS) after scrotal tap and injection of sclerosing agent for the treatment of hydrocele in 5 male. The mean age was 43.2 years, and the gap between the procedure and development of clinical features suggestive of MoS was 1.5-3 months. The neurophysiology studies demonstrated hyper excitability of peripheral nerves. In addition, autonomic dysfunction, severe insomnia, and neuropsychiatric features were observed. Significant VGKC-complex/CASPR-2 antibodies titer were present in all cases. Symptoms resolved spontaneously within 6 months of onset.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860152     DOI: 10.4103/0028-3886.115072

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  4 in total

1.  CASPR2-Related Morvan Syndrome: Autonomic, Polysomnographic, and Neuropsychological Observations.

Authors:  Panda Sudha Swayang; Atchayaram Nalini; Veeramani Preethish-Kumar; Kaviraja Udupa; Ravi Yadav; Seena Vengalil; Sheikh Sultana Reshma; Kiran Polavarapu; Saraswati Nashi; T N Sathyaprabha; Priya Treesa Thomas; Bhat Maya; Rajeshwaran Jamuna; Anita Mahadevan; M Netravathi
Journal:  Neurol Clin Pract       Date:  2021-06

2.  Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.

Authors:  Edvina Galié; Rosaria Renna; Domenico Plantone; Andrea Pace; Mirella Marino; Bruno Jandolo; Tatiana Koudriavtseva
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

Review 3.  Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions.

Authors:  James Varley; Angela Vincent; Sarosh R Irani
Journal:  J Neurol       Date:  2014-12-10       Impact factor: 4.849

4.  Clinical Profile and Treatment Response in Patients with CASPR2 Antibody-Associated Neurological Disease.

Authors:  Sumanth Shivaram; Madhu Nagappa; Doniparthi V Seshagiri; Anita Mahadevan; Yashwanth Gangadhar; T N Sathyaprabha; Vijay Kumavat; Rose D Bharath; Sanjib Sinha; Arun B Taly
Journal:  Ann Indian Acad Neurol       Date:  2021-03-31       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.